Literature DB >> 3928135

Applications and limitations of peripheral blood lymphocyte immunoglobulin light chain analysis in the evaluation of non-Hodgkin's lymphoma.

R E Sobol, R O Dillman, H Collins, J C Griffiths, M R Green, I Royston.   

Abstract

Surface immunoglobulin (sIg) light chain analysis of peripheral blood lymphocytes (PBL) from 63 patients with non-Hodgkin's lymphoma (NHL) was performed to determine the ratio of kappa-bearing lymphocytes to lambda-bearing lymphocytes (kappa/lambda ratio). In 43% an abnormal kappa/lambda ratio was detected, implying the presence of a malignant clone in the peripheral blood (clonal excess). In 67% of cases with an abnormal kappa/lambda ratio, the absolute lymphocyte count was within normal limits and 20% did not have morphologic bone marrow involvement. Light chain analysis of bone marrow aspirates was performed in three of four patients with a circulating clone and normal bone marrow morphology. All three patients had abnormal bone marrow aspirate kappa/lambda ratios. The presence of a circulating clone was associated with morphologic bone marrow involvement (P less than 0.05). Nine patients with documented B-cell NHL were followed with repeated examinations. The presence of a circulating clone persisted in two patients refractory to therapy and in two patients otherwise believed to be in remission. Conversion to an abnormal kappa/lambda ratio occurred in two patients coincident with the development of new bone marrow involvement and in a third patient prior to the onset of frank leukemia. In three instances, the PBL light chain analyses remained within normal limits in patients with stable lymphadenopathy. The kappa/lambda ratio returned to normal in one patient responding to treatment with a partial remission, and remained within normal limits despite progression of lymphadenopathy in one patient, and local disease recurrence in another patient. These findings suggest that the detection of a circulating clone by sIg light chain analysis may be useful as a noninvasive approach to identify disseminated disease activity unsuspected on the basis of morphologic evaluations, but may not reflect the presence, progression, or recurrence of localized tissue lesions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928135     DOI: 10.1002/1097-0142(19851015)56:8<2005::aid-cncr2820560820>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Repeated pentostatin (2'deoxycoformycin)-induced remissions in a patient with advanced chronic lymphocytic leukemia.

Authors:  R O Dillman; A L Yu; C N Qiao
Journal:  West J Med       Date:  1988-03

2.  Lymphocyte surface marker studies in the diagnosis of unexplained lymphocytosis.

Authors:  M C Quantz; J B Robinson; V Sachs; P H Pinkerton
Journal:  CMAJ       Date:  1987-04-15       Impact factor: 8.262

3.  An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells.

Authors:  Shoko Nakayama; Taiji Yokote; Yuji Hirata; Kazuki Iwaki; Toshikazu Akioka; Takuji Miyoshi; Ayami Takayama; Uta Nishiwaki; Yuki Masuda; Toshiyuki Ikemoto; Hidema Tanaka; Yasuichiro Nishimura; Motomu Tsuji; Toshiaki Hanafusa
Journal:  Diagn Pathol       Date:  2012-09-28       Impact factor: 2.644

4.  Circulating lymphoma cells in patients with B & T non-Hodgkin's lymphoma detected by immunoglobulin and T-cell receptor gene rearrangement.

Authors:  M Brada; S Mizutani; H Molgaard; J P Sloane; J Treleaven; A Horwich; M J Peckham
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.